First Time Loading...
G

Guobang Pharma Ltd
SSE:605507

Watchlist Manager
Guobang Pharma Ltd
SSE:605507
Watchlist
Price: 17.38 CNY 4.32% Market Closed
Updated: May 7, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Guobang Pharma Ltd

Wall Street analysts forecast Guobang Pharma Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Guobang Pharma Ltd is 24.48 CNY with a low forecast of 24.24 CNY and a high forecast of 25.2 CNY.

Lowest Forecast
Wall Street Target
24.24 CNY
39% Upside
Average Forecast
Wall Street Target
24.48 CNY
41% Upside
Highest Forecast
Wall Street Target
25.2 CNY
45% Upside
Lowest
Price Target
24.24 CNY
39% Upside
Average
Price Target
24.48 CNY
41% Upside
Highest
Price Target
25.2 CNY
45% Upside
Guobang Pharma Ltd Competitors:
Price Targets
C
214370
Caregen Co Ltd
131% Upside
300026
Tianjin Chase Sun Pharmaceutical Co Ltd
449% Upside
A
506260
Anuh Pharma Ltd
20% Upside
600594
Guizhou Yibai Pharmaceutical Co Ltd
54% Upside
C
214370
Caregen Co Ltd
131% Upside
300026
Tianjin Chase Sun Pharmaceutical Co Ltd
449% Upside
A
506260
Anuh Pharma Ltd
20% Upside
600594
Guizhou Yibai Pharmaceutical Co Ltd
54% Upside
I
249420
Il Dong Pharmaceutical Co Ltd
224% Upside
4502
Takeda Pharmaceutical Co Ltd
20% Upside
BOI
Boiron SA
24% Upside
002626
Xiamen Kingdomway Group Co
42% Upside

Revenue
Forecast

Revenue Estimate
Guobang Pharma Ltd

For the last 4 years the compound annual growth rate for Guobang Pharma Ltd's revenue is 9%. The projected CAGR for the next 2 years is 23%.

9%
Past Growth
23%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Guobang Pharma Ltd

Operating Income forecast
is not available for
Guobang Pharma Ltd

Net Income
Forecast

Net Income Estimate
Guobang Pharma Ltd

For the last 4 years the compound annual growth rate for Guobang Pharma Ltd's net income is 18%. The projected CAGR for the next 2 years is 39%.

18%
Past Growth
39%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Guobang Pharma Ltd's stock price target?
Price Target
24.48 CNY

According to Wall Street analysts, the average 1-year price target for Guobang Pharma Ltd is 24.48 CNY with a low forecast of 24.24 CNY and a high forecast of 25.2 CNY.

What is Guobang Pharma Ltd's Revenue forecast?
Projected CAGR
23%

For the last 4 years the compound annual growth rate for Guobang Pharma Ltd's revenue is 9%. The projected CAGR for the next 2 years is 23%.

What is Guobang Pharma Ltd's Net Income forecast?
Projected CAGR
39%

For the last 4 years the compound annual growth rate for Guobang Pharma Ltd's net income is 18%. The projected CAGR for the next 2 years is 39%.

ALPHA SPREAD
Join more than 134,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.